TTAN vs. VRNA
TTAN (ServiceTitan, Inc) and VRNA (Verona Pharma plc) are both stocks. TTAN operates in Software - Application (Technology), while VRNA operates in Biotechnology (Healthcare). At a 0.05 correlation, their price movements are largely independent.
Performance
TTAN vs. VRNA - Performance Comparison
Loading charts...
Returns By Period
TTAN
- 1D
- 2.59%
- 1M
- 1.61%
- YTD
- -39.73%
- 6M
- -41.59%
- 1Y
- -38.26%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
VRNA
- 1D
- —
- 1M
- —
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
TTAN vs. VRNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
TTAN ServiceTitan, Inc | -39.73% | 3.53% | 1.85% |
VRNA Verona Pharma plc | 0.00% | 130.21% | 16.22% |
Correlation
The correlation between TTAN and VRNA is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.01 |
Correlation (All Time) Calculated using the full available price history since Dec 12, 2024 | 0.05 |
Fundamentals
TTAN:
$6.10B
VRNA:
$9.72B
TTAN:
-$246.61
VRNA:
-$0.69
TTAN:
0.02
VRNA:
57.97
TTAN:
0.00
VRNA:
34.92
TTAN:
$269.57B
VRNA:
$167.65M
TTAN:
$194.32B
VRNA:
$159.52M
TTAN:
-$25.80B
VRNA:
-$40.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TTAN vs. VRNA — Risk / Return Rank
TTAN
VRNA
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
TTAN vs. VRNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ServiceTitan, Inc (TTAN) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TTAN | VRNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | — | — | |
| Sortino ratioReturn per unit of downside risk | — | — | |
| Omega ratioGain probability vs. loss probability | 0.89 | — | — |
| Calmar ratioReturn relative to maximum drawdown | -0.71 | — | — |
| Martin ratioReturn relative to average drawdown | -1.25 | — | — |
Loading charts...
Drawdowns
TTAN vs. VRNA - Drawdown Comparison
Loading charts...
Drawdown Indicators
| TTAN | VRNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -57.26% | — | — |
Max Drawdown (1Y)Largest decline over 1 year | -53.78% | — | — |
Current DrawdownCurrent decline from peak | -50.38% | — | — |
Average DrawdownAverage peak-to-trough decline | -24.02% | — | — |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.73% | — | — |
Volatility
TTAN vs. VRNA - Volatility Comparison
Loading charts...
Volatility by Period
| TTAN | VRNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.50% | — | — |
Volatility (6M)Calculated over the trailing 6-month period | 42.13% | — | — |
Volatility (1Y)Calculated over the trailing 1-year period | 51.38% | — | — |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 50.68% | — | — |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 50.68% | — | — |
Dividends
TTAN vs. VRNA - Dividend Comparison
Neither TTAN nor VRNA has paid dividends to shareholders.
Financials
TTAN vs. VRNA - Financials Comparison
This section allows you to compare key financial metrics between ServiceTitan, Inc and Verona Pharma plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TTAN vs. VRNA - Profitability Comparison
TTAN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ServiceTitan, Inc reported a gross profit of 193.79B and revenue of 268.82B. Therefore, the gross margin over that period was 72.1%.
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.
TTAN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ServiceTitan, Inc reported an operating income of -25.76B and revenue of 268.82B, resulting in an operating margin of -9.6%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.
TTAN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ServiceTitan, Inc reported a net income of -22.82B and revenue of 268.82B, resulting in a net margin of -8.5%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.
Frequently Asked Questions
TTAN and VRNA have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for TTAN and VRNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer